ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV
Key takeaways
- ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV Maham Fatima Mon, June 1, 2026 at 6:37 PM GMT+7 2 min read ADMA ADMA Biologics Inc.
- CEO Adam Grossman stated that the expanded indication allows the company to address the needs of younger immune-compromised patients much earlier in their treatment journey.
- 15 States with the Best Healthcare in the US
ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV Maham Fatima Mon, June 1, 2026 at 6:37 PM GMT+7 2 min read ADMA ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best cheap stocks under $10 to buy in June. On May 4, ADMA Biologics received FDA approval to expand the label for its specialty biologic, ASCENIV, to include pediatric patients aged two years and older. Previously, the treatment was restricted to primary humoral immunodeficiency/PI patients aged 12 and older. This approval follows the completion of a required post-marketing pediatric assessment and marks a significant expansion of the therapy’s reach.
CEO Adam Grossman stated that the expanded indication allows the company to address the needs of younger immune-compromised patients much earlier in their treatment journey. The clinical milestone highlights the success of the company’s pediatric assessment program, which was driven by collaborative efforts between ADMA’s operational teams, medical professionals, and participating families.
15 States with the Best Healthcare in the US